Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of VX-509 in Rheumatoid Arthritis
NCT01830985Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of decernotinib in rheumatoid arthritis (RA), sponsored by Vertex Pharmaceuticals. Started Apr 2013; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01830985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830985.